SynthesisNeurosurgical review2026
Stereotactic radiosurgery for treatment-refractory obsessive-compulsive disorder: a systematic review of targets, targeting methods, lesion geometry, and clinical outcomes.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStereotactic radiosurgery (SRS) is a noninvasive option for carefully selected patients with treatment-refractory obsessive-compulsive disorder (OCD), but the literature is heterogeneous in targets, targeting methods, lesion geometry, and outcomes.
methodsPRISMA-guided systematic review of PubMed, Scopus, and Web of Science. Full-text human studies of radiosurgical capsulotomy for treatment-refractory OCD were included. Narrative synthesis was performed across technical and clinical domains. When ≥3 comparable studies reported the same endpoint, exploratory random-effects single-arm meta-analyses were performed.
resultsTwenty-one OCD-specific studies were included (1999-2024). The anterior limb of the internal capsule (ALIC), particularly the ventral ALIC, was the dominant target. Technique and dose reporting varied across cohorts, with commonly reported maximum doses spanning approximately 120-180 Gy, often using 4-mm collimation and single- or double-shot paradigms. Earlier reports primarily used anatomical MRI/coordinate-based targeting, whereas newer studies increasingly incorporated lesion mapping, tractography, and network-based analyses. Eleven cohorts were eligible for quantitative pooling. The pooled clinical response rate was 57.1% (95% CI, 49.1%-64.9%; I²=21.7%), and pooled remission was 36.8% (95% CI, 26.9%-47.9%; I²=0%). Severe delayed radiation-related injury was uncommon but present (6.4%, 95% CI, 3.1%-12.8%; I²=0%). Mechanistic studies suggested that lesion topography and pathway engagement may be more important than lesion size alone.
conclusionsSRS is a meaningful option for treatment-refractory OCD. The ventral ALIC remains the principal target, but outcomes likely depend on precise target identification and lesion placement. Standardized reporting and prospective evaluation of pathway-informed targeting are needed.
Indexed as
Identifiers
42469526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.